Health · Pharma & Biotech · 5 hrs ago
Lyme vaccine candidate exceeds 70% efficacy but misses trial threshold
An investigational Lyme disease vaccine was tested in a late-stage, placebo-controlled trial.
The candidate was designed to cover six serotypes across four Borrelia species, bacteria that cause Lyme disease.
Its reported vaccine efficacy was over 70%.
But the result fell just short of a preset noninferiority threshold, a benchmark set before the trial.
That means the vaccine did not meet this particular trial measure, despite the efficacy figure.
The available details do not say what happens next or whether further testing is planned.
An investigational Lyme disease vaccine had vaccine efficacy of over 70% in a late-stage trial.
The candidate nevertheless missed a preset noninferiority threshold.
The vaccine covers six serotypes across four Borrelia species.
The trial was placebo-controlled.
- Who
- An investigational Lyme disease vaccine candidate.
- What
- It had vaccine efficacy of over 70% but missed a preset noninferiority threshold in a late-stage trial.
- When
- The report was published on October 27, 2026; the trial date is not stated.
- Where
- Washington, according to the article’s dateline; the trial location is not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Vaccine efficacy
- Over 70%
- Threshold
- Preset noninferiority threshold was missed
- Coverage
- Six serotypes across four Borrelia species